The Role of Combination or Coformulation Products in the Treatment of Type 2 Diabetes


Most patients with type 2 diabetes will require multiple pharmacologic agents as their disease progresses. For second-line therapy and beyond, clinicians now select among several treatment options—including insulin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 agonists, and sodium–glucose cotransporter 2 inhibitors. Although combination or coformulation products can simplify treatment regimens, identifying the best therapies for individual patients can still be daunting. Come explore proven strategies for effective second-line therapies for type 2 diabetes.

This session will be audio-recorded and offered as part of the Home-Study on Demand, included with Premium Registration or available for purchase on-site at the Education Booth.

Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to: 

  1. Review updates to the 2018 American Diabetes Association Standards of Medical Care in Diabetes related to the use of combination therapy or co-formulated products.
  2. Describe the evidence that supports a physiologic approach to treatment intensification using combination or co-formulation products
  3. Discuss contraindications and side effect considerations when recommending co-formulated therapy for glycemic control.
  4. Given a patient case, select among available co-formulation treatment options for add-on therapy.
Jennifer Trujillo,
University of Colorado Denver
Susan Cornell, PharmD, BS, FAPhA
Associate Professor
Midwestern University
Learning Level: Level 2
Track: Clinical Patient Care and Services
Session Time Slot(s): 
Sunday, March 18
3:30 PM - 5:00 PM
Music City Center - Room 104C-D
ACPE Pharmacist: 0202-0000-18-053-L01-P
CEUs Pharmacist: 0.15
Activity Type: